Cytotoxicity-inducing theraputic agent

Patent metadata

Field	Value
Publication number	US-9975966-B2
Application number	US-201715467654-A
Country	US
Kind code	B2
Filing date	Mar 23, 2017
Priority date	Sep 26, 2014
Publication date	May 22, 2018
Grant date	May 22, 2018

Abstract

Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.

First claim

The invention claimed is:

1. A multispecific antigen-binding molecule that comprises a glypican 3 binding domain and a T-cell receptor complex-binding domain, wherein:
(1) the glypican 3 binding domain comprises (i) a heavy chain (H-chain) variable region comprising complementarity determining region (CDR) 1, CDR2, and CDR3 sequences of an H-chain having an amino acid sequence of SEQ ID NO:206 and (ii) a light chain (L-chain) variable region comprising CDR1, CDR2, and CDR3 sequences of an L-chain having an amino acid sequence of SEQ ID NO:223; and
(2) the T-cell receptor complex-binding domain comprises (i) a H-chain variable region comprises CDR1, CDR2, and CDR3 sequences of an H-chain having an amino acid sequence of SEQ ID NO:168 and (ii) an L-chain variable region comprising CDR1, CDR2, and CDR3sequences of an L-chain having an amino acid sequence of SEQ ID NO:223.

2. The multispecific antigen-binding molecule of claim 1 , further comprising a domain comprising an Fc region, wherein the Fc region comprises a mutation in an amino acid sequence selected from the group consisting of SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26.

3. The multispecific antigen-binding molecule of claim 2 , wherein the Fc region comprises a mutation in at least one amino acid residue position selected from the following positions specified by EU numbering:
position 220, position 226, position 229, position 231, position 232, position 233, position 234, position 235, position 236, position 237, position 238, position 239, position 240, position 264, position 265, position 266, position 267, position 269, position 270, position 295, position 296, position 297, position 298, position 299, position 300, position 325, position 327, position 328, position 329, position 330, position 331, and position 332.

4. The multispecific antigen-binding molecule of claim 2 , wherein the Fc region comprises a mutation in at least one amino acid residue selected from the following amino acid residue positions specified by EU numbering:
Arg at amino acid position 234, Ala or Arg at amino acid position 235, Lys at amino acid position 239, and Ala at amino acid position 297.

5. The multispecific antigen-binding molecule of claim 2 , wherein the Fc region further comprises an amino acid mutation that promotes formation of a heterodimeric Fc region.

6. The multispecific antigen-binding molecule of claim 5 , wherein the heterodimeric Fc region comprises a combination selected from the group consisting of:
(1) a first Fc that comprises the amino acid sequence of SEQ ID NO:57, and a second Fc that comprises the amino acid sequence of SEQ ID NO:58; and
(2) a first Fc that comprises the amino acid sequence of SEQ ID NO:60 or 62, and a second Fc that comprises the amino acid sequence of SEQ ID NO:61.

7. The multispecific antigen-binding molecule of claim 1 , which is a bispecific antibody.

8. The multispecific antigen-binding molecule of claim 1 , wherein:
(1) the glypican 3 binding domain comprises (i) an H-chain variable region comprising the amino acid sequence of SEQ ID NO:206 and (ii) an L-chain variable region comprising the amino acid sequence of SEQ ID NO:223; and
(2) the T-cell receptor complex-binding domain comprises (i) an H-chain variable region comprising the amino acid sequence of SEQ ID NO:168 and (ii) an L-chain variable region comprising the amino acid sequence of SEQ ID NO:223.

9. The multispecific antigen-binding molecule of claim 1 , further comprising a domain comprising an Fc region.

10. A bispecific antibody comprising a glypican 3 binding domain and a T-cell receptor complex-binding domain, wherein:
(1) the glypican 3 binding domain comprises (i) an H-chain variable region comprising the amino acid sequence of SEQ ID NO:206, (ii) an H-chain constant region comprising the amino acid sequence of SEQ ID NO:61, (iii) an L-chain variable region comprising the amino acid sequence of SEQ ID NO:223, and (iv) an L-chain constant region comprising the amino acid sequence of SEQ ID NO:63; and
(2) the T-cell receptor complex-binding domain comprises (i) an H-chain variable region comprising the amino acid sequence of SEQ ID NO:168, (ii) an H-chain constant region comprising the amino acid sequence of SEQ ID NO:62, (iii) an L-chain variable region comprising the amino acid sequence of SEQ ID NO:223, and (iv) an L-chain constant region comprising the amino acid sequence of SEQ ID NO:63.

Assignees

• Chugai Pharmaceutical Co Ltd

Inventors

• Nezu Junichi
• Narita Atsushi
• Ishiguro Takahiro
• Sakurai Mika
• Shiraiwa Hirotake
• Hironiwa Naoka
• Igawa Tomoyuki
• Kawai Yumiko

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• C07K16/2809 Primary

  against the T-cell receptor (TcR)-CD3 complex · CPC title

• C07K16/468 Primary

  Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies · CPC title